BME •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 07/27/2026 17:35
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeBME
Market Capitalization2,437.36 mln
Float78.98 mln
Earnings Date07/24/2026
EPS
0.28
Overpriced
P / E
40.29
High premium
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.71
Likely reliable
1-Year Forecast
14.51
Strong upside
Relative Strength
77
/ 100
Strongly outperforming
Business Description
Almirall S.A. is a Spanish biopharmaceutical company founded in 1943 and headquartered in Barcelona, with operations spanning Europe, the United States, the Middle East, Asia, and Africa. The company focuses primarily on treating skin conditions such as psoriasis, acne, and atopic dermatitis, while also offering products that address a broader range of medical areas including cardiovascular, respiratory, and nervous system disorders. Almirall has a growing pipeline of experimental treatments at various stages of development, targeting conditions such as hidradenitis suppurativa, alopecia areata, and skin cancer. The company collaborates with several external research partners, including Novo Nordisk and Evotec, to advance its drug discovery and development efforts.